Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term
Abstract Sub-Optimal deployment of Self expanding interwoven stents (Supera) has been shown to increase the rate of Clinically Driven Target Lesion Revascularization (CD-TLR). Meanwhile, drug coated balloons (DCB) have been shown to reduce CD-TLR in the femoral-popliteal segment in de- novo and rest...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-25634-z |
| _version_ | 1811179177034907648 |
|---|---|
| author | Prakash Krishnan Raman Sharma Sriya Avadhani Arthur Tarricone Allen Gee Serdar Farhan Haroon Kamran Annapoorna Kini Samin Sharma |
| author_facet | Prakash Krishnan Raman Sharma Sriya Avadhani Arthur Tarricone Allen Gee Serdar Farhan Haroon Kamran Annapoorna Kini Samin Sharma |
| author_sort | Prakash Krishnan |
| collection | DOAJ |
| description | Abstract Sub-Optimal deployment of Self expanding interwoven stents (Supera) has been shown to increase the rate of Clinically Driven Target Lesion Revascularization (CD-TLR). Meanwhile, drug coated balloons (DCB) have been shown to reduce CD-TLR in the femoral-popliteal segment in de- novo and restenotic lesions. However, the clinical effects of vessel preparation with DCB in nominal, compressed, and elongated Supera has not been widely studied. The purpose of this study is to assess the outcomes of clinically driven re-intervention, major amputations, and mortality in relation to the use of DCB as vessel preparation in different deployment conditions (nominal, compressed, elongated) of the Supera stent. Patient chart data was collected at a single center hospital between March 2015 and May 2020. All patients were adults (≥ 18 years old) and were treated with at least one (≥ 1) Supera stent. Deployment status was extrapolated from anonymized angiograms. The primary endpoint of this study was CD-TLR. Secondary endpoints included amputation and mortality rates associated with each deployment condition. A total of 670 limbs were treated and patients were followed for 36 months. Nominal stent deployment was observed in 337 limbs, followed by elongated condition (n = 176), then by compressed conditions (n = 159). CD-TLR was observed most frequently with elongated deployment. Drug coated balloons were used as vessel prep prior to stenting and showed a protective effect regardless of deployment status; O.R = 0.44 (CI 0.30–0.66, p < .05). |
| first_indexed | 2024-04-11T06:30:24Z |
| format | Article |
| id | doaj.art-3ea43fde0f4f491a8ea052320414f925 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T06:30:24Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-3ea43fde0f4f491a8ea052320414f9252022-12-22T04:40:05ZengNature PortfolioScientific Reports2045-23222022-12-011211810.1038/s41598-022-25634-zDrug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate termPrakash Krishnan0Raman Sharma1Sriya Avadhani2Arthur Tarricone3Allen Gee4Serdar Farhan5Haroon Kamran6Annapoorna Kini7Samin Sharma8Department of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalDepartment of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai HospitalAbstract Sub-Optimal deployment of Self expanding interwoven stents (Supera) has been shown to increase the rate of Clinically Driven Target Lesion Revascularization (CD-TLR). Meanwhile, drug coated balloons (DCB) have been shown to reduce CD-TLR in the femoral-popliteal segment in de- novo and restenotic lesions. However, the clinical effects of vessel preparation with DCB in nominal, compressed, and elongated Supera has not been widely studied. The purpose of this study is to assess the outcomes of clinically driven re-intervention, major amputations, and mortality in relation to the use of DCB as vessel preparation in different deployment conditions (nominal, compressed, elongated) of the Supera stent. Patient chart data was collected at a single center hospital between March 2015 and May 2020. All patients were adults (≥ 18 years old) and were treated with at least one (≥ 1) Supera stent. Deployment status was extrapolated from anonymized angiograms. The primary endpoint of this study was CD-TLR. Secondary endpoints included amputation and mortality rates associated with each deployment condition. A total of 670 limbs were treated and patients were followed for 36 months. Nominal stent deployment was observed in 337 limbs, followed by elongated condition (n = 176), then by compressed conditions (n = 159). CD-TLR was observed most frequently with elongated deployment. Drug coated balloons were used as vessel prep prior to stenting and showed a protective effect regardless of deployment status; O.R = 0.44 (CI 0.30–0.66, p < .05).https://doi.org/10.1038/s41598-022-25634-z |
| spellingShingle | Prakash Krishnan Raman Sharma Sriya Avadhani Arthur Tarricone Allen Gee Serdar Farhan Haroon Kamran Annapoorna Kini Samin Sharma Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term Scientific Reports |
| title | Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term |
| title_full | Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term |
| title_fullStr | Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term |
| title_full_unstemmed | Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term |
| title_short | Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term |
| title_sort | drug coated balloon improves outcomes of sub optimal supera deployment in the intermediate term |
| url | https://doi.org/10.1038/s41598-022-25634-z |
| work_keys_str_mv | AT prakashkrishnan drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT ramansharma drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT sriyaavadhani drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT arthurtarricone drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT allengee drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT serdarfarhan drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT haroonkamran drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT annapoornakini drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm AT saminsharma drugcoatedballoonimprovesoutcomesofsuboptimalsuperadeploymentintheintermediateterm |